Skip to main content
Elsevier Sponsored Documents logoLink to Elsevier Sponsored Documents
. 2025 Jun 9;43(6):1177–1179. doi: 10.1016/j.ccell.2025.05.009

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

Kevin Bi, Meng Xiao He, Ziad Bakouny, Abhay Kanodia, Sara Napolitano, Jingyi Wu, Grace Grimaldi, David A Braun, Michael S Cuoco, Angie Mayorga, Laura DelloStritto, Gabrielle Bouchard, John Steinharter, Alok K Tewari, Natalie I Vokes, Erin Shannon, Maxine Sun, Jihye Park, Steven L Chang, Bradley A McGregor, Rizwan Haq, Thomas Denize, Sabina Signoretti, Jennifer L Guerriero, Sébastien Vigneau, Orit Rozenblatt-Rosen, Asaf Rotem, Aviv Regev, Toni K Choueiri, Eliezer M Van Allen
PMCID: PMC12165282  PMID: 40494276

Main text

(Cancer Cell 39, 649–661.e1–e5; May 10, 2021)

We, the authors of the paper, characterized the single-cell transcriptomes of cancer and immune cells from patients with advanced clear cell renal cell carcinoma before or after immune checkpoint blockade to identify mechanisms of response or resistance to treatment. In the original published version of the paper, the disease stage for patient P915 was reported as stage IV in Figure 1B and in Table S1. However, a recent re-review of the patient’s clinical course showed that at the time of biopsy, the patient’s disease was in fact stage III, with no distant metastases. We have now provided corrected versions of Figure 1 and tab A from Table S1 to accurately reflect the patient’s staging. As patient stage was not used as a covariate in any analyses, the correction does not affect any results or conclusions of the study. We apologize for any confusion this error may have caused.

graphic file with name gr1.jpg

Figure 1. Characterizing the tumor microenvironment of advanced RCC during therapy

Table S1.

Clinical variables for samples and patients, basic metadata for all cells, and differential expression results for initial Louvain clusters and final cell types

Sample Study ID Age at Dx Sex ICB Duration of ICB Regimen Time from end of ICB to Biopsy ICB Response TKI-exposed Biopsy Site Histology Grade Stage Cells Recovered Post-QC
P55 0600855_T3 57 M aPD-1 24 mo. -2 mo. PR TKI Abdominal Mass Clear cell 3 IV 4637
P915 0600915_T1 58 M aPD-1 + aCTLA-4 2 mo. 3 mo. PR No TKI Kidney Clear cell 3 III 6541
P913 0600913_T1 47 M aPD1 + VEGF TKI 10 mo. 2 mo. SD TKI Lung Clear cell 4 IV 3744
P906 0600906_T1 62 M aPD-1 15 mo. 6 mo. PD TKI Lymph node Papillary 3 IV 2470
P912 0600912_T1 60 M aPD1 + VEGF TKI 17 mo. < 1 mo. NE TKI Lymph node Clear cell 4 IV 280
P76 0600876_T1 68 F No ICB N/A N/A N/A No TKI Kidney Clear cell 4 IV 7912
P916 0600916_T1 61 M No ICB N/A N/A N/A No TKI Lymph node Clear cell 4 IV 316
P90 0600890_T1 71 F No ICB N/A N/A N/A No TKI Kidney Clear cell 4 I 8426

RESOURCES